Brian Hill, MD, PhD, of Cleveland Clinic discusses how Venetoclax may be the best novel agent for patients who are intolerant to Ibrutinib at the 58th ASH Annual Meeting in San Diego, CA.
Venetoclax may become the best Treatment for Patients who are intolerant to Ibrutinib
